{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:12:41Z","timestamp":1761513161329,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.3816\/cbc.2004.n.024","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:07:27Z","timestamp":1221080847000},"page":"208-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Phase II Trial of a Doxorubicin\/Docetaxel Doublet for Locally Advanced and Metastatic Breast Cancer: Results from National Surgical Adjuvant Breast and Bowel Project Trial BP-57"],"prefix":"10.3816","volume":"5","author":[{"given":"Roy E.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stewart J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry C.","family":"Lembersky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleftherios P.","family":"Mamounas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CBC.2004.n.024_bib1","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/jnci\/87.15.1169","article-title":"Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines","volume":"87","author":"Gianni","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2004.n.024_bib2","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1200\/JCO.1995.13.5.1152","article-title":"Paclitaxel as second and subsequent chemotherapy for metastatic breast cancer: Activity independent of prior anthracycline response","volume":"13","author":"Seidman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2004.n.024_bib3","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1200\/JCO.1994.12.8.1621","article-title":"Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I\/II trial of 96-hour infusion","volume":"12","author":"Wilson","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2004.n.024_bib4","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1200\/JCO.1995.13.12.2879","article-title":"Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer","volume":"13","author":"Ravdin","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2004.n.024_bib5","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/oxfordjournals.annonc.a058907","article-title":"A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer","volume":"5","author":"Ten","year":"1994","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2004.n.024_bib6","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1200\/JCO.1995.13.12.2886","article-title":"Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer","volume":"13","author":"Valero","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2004.n.024_bib7","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","article-title":"Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group","volume":"17","author":"Chan","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2004.n.024_bib8","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.2003.02.063","article-title":"Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer","volume":"21","author":"Henderson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2004.n.024_bib9","first-page":"4","article-title":"Paclitaxel (T) following doxorubicin\/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28","volume":"22","author":"Mamounas","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2004.n.024_bib10","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1200\/JCO.2003.12.005","article-title":"The effect on tumor response of adding sequential preoperative docetaxel (taxotere) to preoperative doxorubicin and cyclophosphamide (AC): preliminary results from National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-27","volume":"21","author":"Bear","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2004.n.024_bib11","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1995.13.11.2688","article-title":"Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study","volume":"13","author":"Gianni","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2004.n.024_bib12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/oxfordjournals.annonc.a010717","article-title":"Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic","volume":"7","author":"Gehl","year":"1996","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2004.n.024_bib13","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2001.19.2.314","article-title":"Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer","volume":"19","author":"Nabholtz","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2004.n.024_bib14","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.2003.04.040","article-title":"Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial","volume":"21","author":"Nabholtz","year":"2003","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.3816\/CBC.2004.n.024_bib15","first-page":"84a","article-title":"Doxorubicin and docetaxel (AT) is superior to standard doxorubicin and cyclophosphamide (AC) as 1st line CT for MBC: randomized phase III trial","volume":"57","author":"Nabholtz","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2004.n.024_bib16","first-page":"17","article-title":"Docetaxel in combination with doxorubicin: a phase I dosefinding study","volume":"11","author":"Dieras","year":"1997","journal-title":"Oncology (Huntingt)"},{"key":"10.3816\/CBC.2004.n.024_bib17","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000067771","article-title":"Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer","volume":"64","author":"Aihara","year":"2003","journal-title":"Oncology"},{"key":"10.3816\/CBC.2004.n.024_bib18","first-page":"107a","article-title":"Combination of Taxotere (T) and doxorubicin (a): a South American phase II study in first line treatment (TT) of metastatic breast cancer (MBC)","volume":"19","author":"Vallejos","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2004.n.024_bib19","first-page":"122","article-title":"Combination of Taxotere (T) and Doxorubicin (A): an Asian phase II study in first line treatment (TT) of metastatic breast cancer (MBC)","volume":"19","author":"Muthalib","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2004.n.024_bib20","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1023\/A:1026418831238","article-title":"Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer","volume":"10","author":"Misset","year":"1999","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2004.n.024_bib21","first-page":"4082","article-title":"Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer","volume":"6","author":"Itoh","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CBC.2004.n.024_bib22","first-page":"34","article-title":"Combination docetaxel\/cyclophosphamide in patients with advanced solid tumors","volume":"11","author":"Valero","year":"1997","journal-title":"Oncology (Huntingt)"},{"key":"10.3816\/CBC.2004.n.024_bib23","first-page":"35a","article-title":"Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC)","volume":"21","author":"Mackey","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2004.n.024_bib24","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3816\/CBC.2002.n.036","article-title":"Phase II trial of a doxorubicin, docetaxel, and cyclophosphamide triplet for locally advanced and metastatic breast cancer: results from NSABP BP-58","volume":"3","author":"Smith","year":"2002","journal-title":"Clin Breast Cancer"},{"key":"10.3816\/CBC.2004.n.024_bib25","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.3816\/CBC.2004.n.024_bib26","series-title":"Statistical methods","first-page":"120","author":"Snedecor","year":"1980"},{"key":"10.3816\/CBC.2004.n.024_bib27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.3816\/CBC.2004.n.024_bib28","series-title":"Survival analysis: Techniques for censored and truncated data","first-page":"109","author":"Klein","year":"1997"},{"key":"10.3816\/CBC.2004.n.024_bib29","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.2000.18.12.2369","article-title":"Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196","volume":"18","author":"Sparano","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2004.n.024_bib30","first-page":"3766","article-title":"In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells","volume":"6","author":"Zeng","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CBC.2004.n.024_bib31","first-page":"16","article-title":"Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations","volume":"25","author":"D'Incalci","year":"1998","journal-title":"Semin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682091170369X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682091170369X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:07:56Z","timestamp":1761512876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152682091170369X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["S152682091170369X"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2004.n.024","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2004,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II Trial of a Doxorubicin\/Docetaxel Doublet for Locally Advanced and Metastatic Breast Cancer: Results from National Surgical Adjuvant Breast and Bowel Project Trial BP-57","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2004.n.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}